Rimegepant for Acute Migraine Treatment in Children and Adolescents
This study is looking for children and adolescents aged 6 to 17 who experience migraines to test a medication called rimegepant (also known as BHV3000). The goal is to see if rimegepant, at either a 75 mg or 50 mg dose, can effectively stop migraine pain compared to a placebo (an inactive substance). Researchers will measure how many participants are completely pain-free two hours after taking the medication. You could be eligible if you have a history of migraines for at least six months. The study is currently unclear on its recruitment status.
- Study design
- This is an interventional, randomized study involving 2100 participants. It compares rimegepant to a matching placebo.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary endpoint is measured at 2 hours post-dose, but overall follow-up duration is not specified.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Randomized Study in Children and Adolescents With Migraine: Acute Treatment
At a glance
Conditions
Where it's being run
245 sites across 78 statesStudy leadership
- Pfizer CT.gov Call Center · STUDY_DIRECTOR · Pfizer
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- To evaluate the efficacy of rimegepant compared with placebo in the acute treatment of migraine in adolescent population (≥ 12 to <18 years of age) as measured by pain freedom using the number of patients reporting no pain.2 hours post-dose
Pain freedom will be assessed in adolescent population (≥ 12 to \< 18 years of age) on a 4-point numeric rating scale (0=none, 1=mild, 2=moderate, 3=severe).